Effect of Minimally Invasive Surfactant Therapy Versus Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome The OPTIMIST: A Randomized Clinical Trial. Issue 3 (24th September 2022)

• Record Type: Journal Article
• Authors: Dargaville, P.A.; Kamlin, O.F.; Orsini, F.; Wang, X.; De Paoli, A.G.; Kanmaz Kutman, H.G.; Cetinkaya, M.; Aiyappan, A.; Lemyre, B.; Kuo, S.; Rajadurai, V.S.; O'Shea, J.; Biniwale, M.; Ramanathan, R.; Kushnir, A.; Bader, D.; Thomas, M.R.; Mallinath, C.; Buksh, M.J.; Bhatia, R.; Sullivan, C.L.; Shinwell, E.S.; Dyson, A.; Barker, D.P.; Kugelman, A.; Donovan, T.J.; Tauscher, M.K.; Murthy, V.; Ali, S.K.M.; Yossuck, P.; Clark, H.W.; Soll, R.F.; Carlin, J.B.; Davis, P.G.;
• Is Part Of: Obstetric anesthesia digest. Volume 42:Issue 3(2022)
• Page Start: 138
• Page End: 139
• Publication Date: 2022-09-24
• Subjects: Neonatal Morbidity and Mortality; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000853596.47739.ff
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( JAMA . 2021;326:2478–2487) Continuous positive airway pressure (CPAP) is recommended for newly born preterm infants. A previous meta-analysis of clinical trials compared CPAP to intubation and ventilation in terms of death or bronchopulmonary dysplasia and found CPAP had a relative risk of 0.91 [95% confidence interval (CI), 0.84-0.99]. In the studies used in meta-analysis, exogenous surfactant was administered only to infants with relatively high levels of inspired oxygen. This study, the OPTIMIST-A trial aimed to determine whether minimally invasive surfactant therapy, using a thin catheter, would lower the incidence of death and/or bronchopulmonary dysplasia.